A5023400259- Pulmonary Hypertension Research and Treatments
- Vascular Anomalies and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Transplantation: Methods and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Intracranial Aneurysms: Treatment and Complications
- Cerebrovascular and Carotid Artery Diseases
- Liver Disease and Transplantation
- Mechanical Circulatory Support Devices
- Cardiac tumors and thrombi
- Cardiac Arrhythmias and Treatments
- Vascular Malformations Diagnosis and Treatment
- Moyamoya disease diagnosis and treatment
- Cardiac Valve Diseases and Treatments
- Diet and metabolism studies
- Eosinophilic Disorders and Syndromes
- Peptidase Inhibition and Analysis
- Acute Ischemic Stroke Management
- Gut microbiota and health
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
Aichi Cancer Center
2025
University of Miyazaki
2025
Okayama Medical Center
2015-2024
National Hospital Organization
2015-2024
Megmilk Snow Brand (Japan)
2010-2018
Toho University Medical Center Sakura Hospital
2015-2017
Tohoku University
1986-2017
National Cerebral and Cardiovascular Center
2017
Kyorin University
2017
Toho University
2015-2017
Background— Although balloon pulmonary angioplasty (BPA) for inoperable patients with chronic thromboembolic hypertension was first reported over a decade ago, its clinical application has been restricted because of limited efficacy and complications. We have refined the procedure BPA to maximize efficacy. Methods Results— Sixty-eight consecutive underwent BPA. evaluated artery diameters determined appropriate size by using intravascular ultrasound. performed in staged fashion multiple,...
Background— Balloon pulmonary angioplasty (BPA) is an alternative therapy for patients with chronic thromboembolic hypertension who are ineligible endarterectomy—the standard therapy. Currently, most reported results of BPA from relatively small cohorts treated at single centers. The present study evaluated the safety and efficacy based on a multicenter registry. Methods Results— A total 308 (62 men 246 women; mean age, 61 years) underwent 1408 procedures 7 institutions in Japan. Data were...
Balloon pulmonary angioplasty (BPA) is an alternative therapy for patients with chronic thromboembolic hypertension who are ineligible standard therapy, endarterectomy. Although there several classifications of vascular lesions, these based on the features specimen removed during Because organized thrombi not balloon angioplasty, we attempted to establish a new classification lesions angiographic images. We evaluated success and complication rate BPA in accordance location morphology...
Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH) therapy and balloon angioplasty (BPA) are currently accepted therapies for chronic thromboembolic (CTEPH). This international CTEPH Registry identifies clinical characteristics of patients, diagnostic algorithms treatment decisions in a global context.1010 newly diagnosed consecutive patients were included the registry between February 2015 September 2016. Diagnosis was confirmed by right heart catheterisation,...
The trend of the initial treatment strategy for pulmonary arterial hypertension (PAH) has changed from monotherapies to upfront combination therapies. This study analyzed treatments and outcomes in Japanese patients with PAH, using data Japan PH Registry (JAPHR), which is first organized multicenter registry PAH Japan.
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on long-term survival patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon angioplasty (BPA), an approved oral drug therapy guanylate cyclase stimulator riociguat. current registry aimed to evaluate effect these new therapeutic approaches in a worldwide...
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by a fibrotic thrombus persisting and obliterating the lumen of arteries; its pathogenesis remains poorly defined. This study investigates potential contribution for progenitor cell types in development vascular obliteration remodeling CTEPH patients. Endarterectomized tissue from patients undergoing thromboendarterectomy was collected examined structure cellular composition. Our data show an organized fibrin network...
Platelet-derived growth factor (PDGF) and its receptor are known to be substantially elevated in lung tissues pulmonary arterial smooth muscle cells (PASMC) isolated from patients animals with hypertension. PDGF has been shown phosphorylate activate Akt mammalian target of rapamycin (mTOR) PASMC. In this study, we investigated the role PDGF-mediated activation signaling regulation cytosolic Ca 2+ concentration cell proliferation. activated Akt/mTOR pathway and, subsequently, enhanced...
Background: Balloon pulmonary angioplasty (BPA) has become an alternative treatment for inoperable patients with chronic thromboembolic hypertension. Lung injury (LI) is a major complication of BPA and may attenuate the benefits BPA. Therefore, we conducted retrospective study to evaluate association between patient procedural characteristics LI in Methods Results: We reviewed 76 hypertension who underwent multidetector computed tomography scanning pre- post-BPA procedures. performed on 1247...
Idiopathic/heritable pulmonary arterial hypertension (I/HPAH) carries a poor prognosis despite the therapeutic options available. Patient survival from Western countries has been reported, but data Asia are scarce. We retrospectively reviewed 56 patients with I/HPAH treated at single referral center in Japan. Survival analyses were conducted using Kaplan–Meier method log-rank test. Variables associated determined Cox proportional hazard model. There 41 women (73%) and mean age diagnosis was...
Factors contributing to the development of a fibrotic vascular scar and pulmonary remodeling leading chronic thromboembolic hypertension (CTEPH) are still unknown. This study investigates potential contribution multipotent progenitor cells myofibroblasts progression CTEPH. Histological examination endarterectomized tissues from patients with CTEPH identified significant neointimal formation. Morphological heterogeneity was observed in isolated these tissues, including network-like growth...
Pulmonary tumor thrombotic microangiopathy is a lethal, yet difficult to diagnose, complication of gastrointestinal carcinoma. Even if properly diagnosed, there no treatment, especially after circulatory collapse. We herein report case pulmonary with failure due hypertension. The patient was temporarily successfully treated imatinib, an inhibitor the platelet-derived growth factor receptor. hypertension dramatically ameliorated and able be weaned from percutaneous cardiopulmonary support...
Background: The appropriate dose range of epoprostenol is thought to be 25-40 ng · kg-1 min-1 based on the results previous studies showing that therapy reduced mean pulmonary artery pressure (mPAP) by 12-22% and vascular resistance (PVR) 32-53% compared with baseline values in patients idiopathic arterial hypertension (IPAH). However, efficacy treatment IPAH >40 has not been determined this was aim present study. Methods Results: study group comprised 16 consecutive patients, none whom...
Pulmonary vascular remodeling occurs in patients with chronic thromboembolic pulmonary hypertension (CTEPH). One factor contributing to this wall thickening is the proliferation of artery smooth muscle cells (PASMC). Store-operated Ca 2+ entry (SOCE) and cytosolic free concentration ([Ca ] cyt ) PASMC are known be important cell hypertension. Rapamycin widely for its antiproliferative effects injured coronary arteries. Although several reports have suggested favorable rapamycin animal models...
A microfluidic cell stretch device was developed to investigate the effects of stretching stress on pulmonary artery smooth muscle (PASMC) proliferation in arterial hypertension (PAH). The harbors upper culture and lower control channels, separated by a stretchable poly(dimethylsiloxane) membrane that acts as substrate. channel inlet connected vacuum pump via digital switch-controlled solenoid valve. For cyclic at heartbeat frequency (80 bpm), open or close time for each valve set 0.38 s....